ReviewToxins2016
Targeting Staphylococcus aureus Toxins: A Potential form of Anti-Virulence Therapy.
Review in Toxins, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
144 citing papers in PubMed, 311 citations in OpenAlex.
- Review
- AMP-36 exhibits potent therapeutic efficacy against MRSA pneumonia through membrane-target mechanism.Scientific reports · 2026Article
- Antibacterial Activity of the Pyrazolone Copper Complex P-FAH-Cu-phen AgainstMicroorganisms · 2026Article
- Beyond Antibiotics: Therapeutic Strategies Utilizing Probiotics and Bacteriophages Against Drug-ResistantMicroorganisms · 2026Review
- Multitarget Mechanisms of (‒)‒Epigallocatechin-3-Gallate Against MRSA: From SraP L-Lectin Targeting to Synergistic Antibiotic Effects.Pathogens (Basel, Switzerland) · 2026Article
- A comprehensive review of emerging therapeutic strategies against methicillin-resistantFrontiers in microbiology · 2026Review
- Influence of substitution patterns on the antimicrobial properties of pyrrole sulfonamide scaffolds.Frontiers in chemistry · 2026Article
- Tanshinone I as a novel therapeutic agent targeting von Willebrand factor-binding protein to mitigateVirulence · 2025Article
- Drug Repurposing: An Emerging Strategy inJournal of microbiology and biotechnology · 2025Review
- Protective effect of tanshinone IIA against Listeria monocytogenes infection in vitro and in vivo.Scientific reports · 2025Article
- Synthesis, characterization, molecular docking studies, and theoretical calculations of novel Ni (II), Cu (II), and Zn (II) complexes based on benzothiazole derivative.BMC chemistry · 2025Article
- Toxic Shock Syndrome Toxin-1 (TSST-1) inToxins · 2025Review
- Human neutrophil defensin-1 binding increases histidine kinase activity of SaeS inBiochemistry and biophysics reports · 2025Article
- Review
- DisarmingPathogens (Basel, Switzerland) · 2025Review
- Molecular Epidemiology Clinical Manifestations, Decolonization Strategies, and Treatment Options of Methicillin-ResistantPathogens (Basel, Switzerland) · 2025Review
- Novel inhibition ofApplied and environmental microbiology · 2025Article
- The Acari Hypothesis, VII: accounting for the comorbidity of allergy with other contemporary medical conditions, especially metabolic syndrome.Frontiers in allergy · 2025Article
- Medicinal plants: bioactive compounds, biological activities, combating multidrug-resistant microorganisms, and human health benefits - a comprehensive review.Frontiers in immunology · 2025Review
- Virulence traits and bacterial interactions within the complex microbial population in urinary double-J catheters.Frontiers in microbiology · 2025Article
84 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Staphylococcus aureus is an opportunistic pathogen and the leading cause of a wide range of severe clinical infections. The range of diseases reflects the diversity of virulence factors produced by this pathogen. To establish an infection in the host, S. aureus expresses an inclusive set of virulence factors such as toxins, enzymes, adhesins, and other surface proteins that allow the pathogen to survive under extreme conditions and are essential for the bacteria's ability to spread through tissues. Expression and secretion of this array of toxins and enzymes are tightly controlled by a number of regulatory systems. S. aureus is also notorious for its ability to resist the arsenal of currently available antibiotics and dissemination of various multidrug-resistant S. aureus clones limits therapeutic options for a S. aureus infection. Recently, the development of anti-virulence therapeutics that neutralize S. aureus toxins or block the pathways that regulate toxin production has shown potential in thwarting the bacteria's acquisition of antibiotic resistance. In this review, we provide insights into the regulation of S. aureus toxin production and potential anti-virulence strategies that target S. aureus toxins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.